Inicio
Resultado de la búsqueda
2 búsqueda de la palabra clave 'proteasome inhibitor'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma / Kenny Mauricio Gálvez Cárdenas
Título : Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2021 Títulos uniformes : Future Oncology Idioma : Inglés (eng) Palabras clave : effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5786 Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2021.
Obra : Future Oncology
Idioma : Inglés (eng)
Palabras clave : effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5786 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001715 AC-2021-036 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-036Adobe Acrobat PDF Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study / Kenny Mauricio Gálvez Cárdenas
Título : Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2020 Títulos uniformes : Leukemia and Lymphoma Idioma : Inglés (eng) Palabras clave : Multiple myeloma Latin America autologous stem cell transplantation proteasome inhibitor Resumen : The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally. Mención de responsabilidad : Camila Peña , Eloisa Riva , Natalia Schutz , Luz Tarín-Arzaga , Humberto Martínez-Cordero , Virginia Bove , Rocío Osorio , Mauricio Chandía , Cecilia Beltrán , Javier Schulz , Daniela Cardemil , Carolina Contreras , Carmen Gloria Vergara , Javiera Donoso , Marcela Espinoza , Gabriel La Rocca , Hernán López-Vidal , Pilar León , Christine Rojas Hopkins , Pablo Soto , Sandra Aranda , Vivianne Torres , Macarena Roa , Paola Ochoa , Patricio Jose Duarte , Guillermina Remaggi , Sebastián Yantorno , Ariel Corzo , Soledad Zabaljauregui , Claudia Shanley , Sergio Lopresti , Sergio Orlando , Verónica Verri , Luis Quiroga , Carlos García , Vanesa Fernández , Jhoanna Ramirez , Alicia Molina , María Pacheco , Alex Mite , Inés Reyes , Brenner Sabando , Francisca Ramírez , Claudia Sossa , Virginia Abello , Henry Idrobo , Kenny Mauricio Galvez Cardenas , Domingo Saavedra , Guillermo Quintero , Raimundo Gazitúa , Lina Gaviria , Rigoberto Gomez , Mónica Osuna , Alicia Henao-Uribe , Omar Cantú-Martínez , Referencia : Leuk Lymphoma. 2020 Dec;61(13):3112-3119. DOI (Digital Object Identifier) : 10.1080/10428194.2020.1804558 PMID : 32844699 En línea : https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1804558 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5127 Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2020.
Obra : Leukemia and Lymphoma
Idioma : Inglés (eng)
Palabras clave : Multiple myeloma Latin America autologous stem cell transplantation proteasome inhibitor Resumen : The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally. Mención de responsabilidad : Camila Peña , Eloisa Riva , Natalia Schutz , Luz Tarín-Arzaga , Humberto Martínez-Cordero , Virginia Bove , Rocío Osorio , Mauricio Chandía , Cecilia Beltrán , Javier Schulz , Daniela Cardemil , Carolina Contreras , Carmen Gloria Vergara , Javiera Donoso , Marcela Espinoza , Gabriel La Rocca , Hernán López-Vidal , Pilar León , Christine Rojas Hopkins , Pablo Soto , Sandra Aranda , Vivianne Torres , Macarena Roa , Paola Ochoa , Patricio Jose Duarte , Guillermina Remaggi , Sebastián Yantorno , Ariel Corzo , Soledad Zabaljauregui , Claudia Shanley , Sergio Lopresti , Sergio Orlando , Verónica Verri , Luis Quiroga , Carlos García , Vanesa Fernández , Jhoanna Ramirez , Alicia Molina , María Pacheco , Alex Mite , Inés Reyes , Brenner Sabando , Francisca Ramírez , Claudia Sossa , Virginia Abello , Henry Idrobo , Kenny Mauricio Galvez Cardenas , Domingo Saavedra , Guillermo Quintero , Raimundo Gazitúa , Lina Gaviria , Rigoberto Gomez , Mónica Osuna , Alicia Henao-Uribe , Omar Cantú-Martínez , Referencia : Leuk Lymphoma. 2020 Dec;61(13):3112-3119. DOI (Digital Object Identifier) : 10.1080/10428194.2020.1804558 PMID : 32844699 En línea : https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1804558 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5127 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001386 AC-2020-063 Archivo digital Producción Científica Artículos científicos Disponible